Primary regulatory
Pentadecapeptide BPC 157 for Acute Grade II Hamstring Strain (NCT07437547)
Phase 2 randomized, double-blind, placebo-controlled trial sponsored by Hudson Biotech, 120 planned participants, recruiting with estimated primary completion 2027. No results posted.
ClinicalTrials.govPublished Feb 27, 2026Accessed Jul 28, 2026
Registry record
Source metadata
- Publisher
- ClinicalTrials.gov
- Source type
- Primary regulatory
- Registry ID
clinicaltrials-bpc157-hamstring-2026
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.